Skip to content Skip to sidebar Skip to footer

Newsletter

Biotech Stocks

T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!

Prescient Therapeutics' (ASX:PTX) trial of PTX-100 against T-Cell Lymphoma is well and truly underway now with 8 out of 16 trial sites set up. This significant milestone provides significant hope to sufferers of this disease as well as to the company's investors. What are the Best ASX Biotech Stocks to invest in right now? Check our…

ByNick SundichMarch 17, 2026

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent cliff is, it is is one of the most consequential forces in global pharmaceuticals. The concept of a big pharma's drug losing exclusivity and having…

ByNick SundichMarch 16, 2026

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear, and arguably feared more and more as the week with trading suspended went on. Namely, its most advanced clinical trial for Efti is all over red rover! While it is not the end of the company,…

ByNick SundichMarch 13, 2026

ASX All Ordinaries Stocks: Here’s Why These 8 Companies Joined the Club In the Latest Rebalance!

Twice a year, specifically on the third Fridays of March and September, the list of ASX All Ordinaries Stocks changes as stocks are added and demoted. Their promotions and demotions happen for various reasons that all feed into an increase or decrease in the company's market capitalisation. In this article, we look at 8 companies that…

ByNick SundichMarch 12, 2026

Here are 4 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own one of the large cap biotechs, you are betting that major milestones (such as clinical trial completions and decisions on regulatory approval) will occur right on cue and that they will be favourable to the…

ByNick SundichFebruary 24, 2026

If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child

We thought this was a perfect time to ponder the question,' Why share prices fall after a capital raising', in light of what happened with Botanix Pharmaceuticals (ASX:BOT). Its shares fell 33% in less than an hour of trading. Now, shouldn't investors be happy that the company has $45m more cash? Let's just say that…

ByNick SundichFebruary 18, 2026

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The company now has a substantially larger market awaiting us, and while its commercialisation strategy for ColoSTAT has changed, this strategy has been successful. Wait, has Rhythm received TGA approval? Yes and no - it's a long…

ByNick SundichFebruary 17, 2026

Here are some ASX stocks that will benefit from a higher AUD, and stocks that will lose

The Aussie dollar has been surging in recent weeks and there are ASX stocks that will benefit from a higher AUD - as well as some that will lose. We cannot be certain how much longer this run will go on for, but we do know it is on a run right now. After several quarters…

ByNick SundichFebruary 16, 2026

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon following a tenure of nearly 3 years. It was clear that something had to give, but this is still a shock as it occurred a day before company results and resulted in McKenzies' tenure lasting…

ByNick SundichFebruary 11, 2026

This company just made an IND submission to the US FDA, here’s why its a big step!

Imagion Biosystems (ASX:IBX) just made a IND submission. This is a big deal for the company, and we thought it would be the perfect time to explain to investors just what this means. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"] [/sg_popup] Here's what you need to know about…

ByNick SundichFebruary 10, 2026

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

T-Cell Lymphoma is a very deadly cancer, but this ASX stock has a treatment in a Phase 2 trial!

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

ASX All Ordinaries Stocks: Here’s Why These 8 Companies Joined the Club In the Latest Rebalance!

Here are 4 ASX biotechs with major milestones coming right up!

If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Here are some ASX stocks that will benefit from a higher AUD, and stocks that will lose

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

This company just made an IND submission to the US FDA, here’s why its a big step!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Add Your Heading Text Here